Associate Professor at MD Anderson Cancer Center
Oncology
Dr. Michael J. Overman, MD
|
|
Give Review
Michael Overman is an expert in the field of Oncology. He researched medicine at Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a top medical university. Johns Hopkins University School of Medicine is ranked 3/29 in Research/PrimaryCare. Dr. Michael J. Overman has written publications. He has 66 publications published with PubMed. The lastest paper is: 'Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation.
- Retrospective Analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction.
- From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.
- The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base.
- Challenges of efficacy assessments in pseudomyxoma peritonea.
- Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
- Association between KRAS mutation and lung metastasis in advanced colorectal Cancer.
- Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression.
- Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer.
- A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal Cancer ...
- Clinicopathologic Characteristics and Gene Expression Analyses of Non-KRAS 12/13, RAS-Mutated Metastatic Colorectal Cancer.
- Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenoCarcinoma.
- Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic Cancer?
- Multicenter retrospective analysis of metastatic colorectal Cancer (CRC) with high-level microsatellite instability (MSI-H).
- Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
- Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic Ductal adenocarcinoma.
- Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA mutations.
- Small bowel adenoCarcinomas-existing evidence and evolving paradigms.
- Improving the AJCC/TNM staging for adenoCarcinomas of the appendix: the prognostic impact of histological grade.
- High-level Microsatellite Instability in Appendiceal Carcinomas.
- The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic Cancer.
- Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
- Pathologic complete response in poorly differentiated adenoCarcinomas of the appendix: A case series.
- Palliative Venting Gastrostomy in Patients with Malignant Bowel Obstruction and Ascites.
- Adjuvant Chemotherapy With FOLFOX for Primary Colorectal Cancer Is Associated With Increased Somatic Gene Mutations and Inferior Survival in Patients Undergoing Hepate...
- A Population-Based Comparison of AdenoCarcinoma of the Large and Small Intestine: Insights Into a Rare Disease.
- Fatal diffuse alveolar damage associated with oxaliplatin administration.
- Lost in Translation: A Fisherman's Tale.
- Is Malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity?
- Is resection of coloRectal liver metastases after a second-line chemotherapy regimen justified?
- High survival rate after two-stage resection of advanced coloRectal liver metastases: response-based selection and complete resection define outcome.
- Prognostic value of lymph node evaluation in small bowel adenocarcinoma: Analysis of the surveillance, epidemiology, and end results database.
- Surgical strategies for synchronous coloRectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?
- Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
- Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal Cancer.
- Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal Cancer: efficacy and circulating angiogenic biomarkers associated with...
- Modern systemic chemotherapy in surgically unresectable Neoplasms of appendiceal origin: a single-institution experience.
- Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.
- Improved survival in metastatic colorectal Cancer is associated with adoption of hepatic resection and improved chemotherapy.
- Phase II study of capecitabine and oxaliplatin for advanced adenoCarcinoma of the small bowel and ampulla of Vater.
- Recent advances in the management of adenoCarcinoma of the small intestine.
- Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic coloRectal metastases.
- Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenoCarcinoma.
- Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid Tumors.
- Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid Tumors.
- Aggressive combined modality therapy for recurrent colorectal Cancer involving the duodenum and pancreas: a report of 5 cases.
- EGFR-targeted therapies in colorectal Cancer.
- The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal Cancer.
- Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal Cancer.
- Rare but Real.
- Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal Cancer.
- A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in Cancer patients.
- Systemic chemotherapy and surgical cytoreDuction for poorly differentiated and signet ring cell adenocarcinomas of the appendix.
- Is there a role for adjuvant therapy in resected adenoCarcinoma of the small intestine.
- Immunophenotype and molecular characterisation of adenoCarcinoma of the small intestine.
- The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
- Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro.
- Doxorubicin-resistant variants of human prostate Cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic dru...
- Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration.
- Second-line chemotherapy use in metastatic colon Cancer varies by disease responsiveness.
- Systematic survey of therapeutic trials for metastatic colorectal Cancer: room for improvement in the critical pathway.
- Picking the right road for metastatic colorectal Cancer patients.
- Durable complete responses in metastatic colorectal Cancer treated with chemotherapy alone.
- Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer.
- Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.
Schools
Johns Hopkins Univ Sch Of Med
Harbor UCLA Med Center
Md Anderson
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
Harbor - UCLA Medical Center -
Johns Hopkins University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1285726281 | |
| NPPES Provider LastName | OVERMAN | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 331.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 4.23 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285726281 |
| Last Name Of The Provider | OVERMAN |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Lori A. Leslie, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anita Sabichi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard P. Baltz, MD |
|
Dr. Bhuvana Sagar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sewa S. Legha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cheryl F. Hirsch-Ginsberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edmund S. Kopetz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hartmut K. Koeppen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Isabella C. Glitza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacy L. Moulder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chad Pecot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nageshwara V. Dasari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cathy Eng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Florencia M. McAllister, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Chitra Hosing, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yan Zhou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Aman U. Buzdar, MB
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|